Weekly Highlights: Leadership Changes at Johnson & Johnson and Zai Lab; Anti-Commercial Bribery Guidelines Issued
Johnson & Johnson
Medical Device R&D and Manufacturer
BeOne
Developer of Molecular Targeted and Immune Anti-Tumor Drugs
Walvax
Human Vaccine Research and Development, Manufacturer
AstraZeneca
Pharmaceutical Technology Research and Development Provider
"Weekly Highlights"
"Weekly Highlights" is a column launched by Siqi Club to summarize the major events in the pharmaceutical industry over the past week, covering the latest policy updates, news, pharmaceutical finance, and drug approval progress.
Personnel Changes
HUMAN RESOURCES
Zai Lab's Greater China Chief Commercial Officer Departs, Former Simcere Executive Takes Over
According to a report by "Jiemian News" on April 22, Liang Yi, the current Chief Commercial Officer of Greater China and President of Greater China at Zai Lab, will leave the company on April 30. His responsibilities will be assumed by Zhu Tong, the former Chief Operating Officer of Simcere Zaiming and Senior Vice President of Simcere Pharmaceuticals.
General Manager and Director of Shiyao Innovative Pharmaceuticals Resign
On April 22, Innovation Pharmaceuticals of Shijiazhuang (Xinuole) announced that the board had received written resignation reports from General Manager Mr. Han Feng and Director Mr. Wang Huaiyu.
Johnson & Johnson Appoints New Executive in China, Joining from Roche
According to "Luo Shi Xiong" news, Johnson & Johnson announced that Chen Yanli will assume the role of Human Resources Leader for Johnson & Johnson Medical Technologies China & OneHR China, effective April 29. She will join the Johnson & Johnson Medical Technologies China Board and the Asia-Pacific Human Resources Management Team.
Policy Brief
POLICY
Notice on Anti-Commercial Bribery Issued, Oversight of Pharmaceutical Representatives Tightened
Recently, the Hubei Provincial Market Supervision Administration released the "Hubei Province Pharmaceutical Enterprises Anti-Commercial Bribery Compliance Management Guidelines (Trial)" (hereinafter referred to as the "Compliance Guidelines"), which clearly defines concepts such as pharmaceutical enterprises, commercial bribery, and compliance. It also proposes three key assessment scenarios, among others.
Pharmaceutical News Updates
PHARMA
BeOne Medicines' Anti-PD-1 Monoclonal Antibody Approved for Three Lung Cancer Indications in the EU
On April 23, BeOne Medicines announced that the European Commission (EC) has approved tislelizumab for first-line and second-line treatment of three non-small cell lung cancer (NSCLC) indications. This is the second approval for tislelizumab in the region.
Walvax Biotechnology Co., Ltd. Terminates Development of Recombinant COVID-19 Vaccine
On April 24, Walvax Biotechnology Co., Ltd. announced that the company has decided to terminate the clinical trial of the recombinant novel coronavirus vaccine (chimpanzee adenovirus vector) developed by its wholly-owned subsidiary, Beijing Weida Biotechnology Co., Ltd.
And誉医药 "Epagortinib" Receives FDA Orphan Drug Designation
On April 25, Abbisko Therapeutics announced on its official WeChat account that its self-developed, highly selective small molecule FGFR4 inhibitor Irpagratinib (ABSK011) had been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Hepatocellular Carcinoma (hereinafter referred to as HCC).
Pharmaceutical Finance
BUSINESS
AstraZeneca's First Quarter Revenue Increased by 19% Year-over-Year
On April 25, AstraZeneca announced its Q1 2024 financial report. During the reporting period, total revenue reached $12.679 billion, increasing by 19% year-on-year, including product revenue of $12.177 billion, up 18% year-on-year.
Sumitomo Pharma Announces Establishment of Trading Company in China
On April 24, Sumitomo Pharma Investments (China) Co., Ltd. announced the establishment of its wholly-owned subsidiary, Sumitomo Pharma Trading (Suzhou) Co., Ltd., which will handle the import and sales of finished pharmaceutical products, as well as provide warehousing, storage, and logistics services.
$1 Billion Latest Collaboration! BI Expands Liver Disease Focus Again
On April 22, Boehringer Ingelheim (BI) announced a collaboration with Ochre Bio to discover novel first-in-class regenerative therapies for chronic liver disease. Under the terms of the agreement, Ochre Bio will receive a $35 million upfront payment and near-term research milestone payments. If subsequent milestones are achieved progressively, the total value of the deal could exceed $1 billion.
ClickRead the Original Text Learn More